Health
Interleukin-6 inhibitors appear to be a more effective treatment for COVID-19 – News-Medical.Net
New research from Boston Medical Center found that patients experiencing severe COVID-19 symptoms had improved outcomes when administered an Interleukin-6 (IL6ri) inhibitor, sarilumab or tocilizumab, given to mediate severe systemic inflammatory responses.
New research from Boston Medical Center found that patients experiencing severe COVID-19 symptoms had improved outcomes when administered an Interleukin-6 (IL6ri) inhibitor, sarilumab or tocilizumab, given to mediate severe systemic inflammatory responses.
The treatment was more effective when administered earlier in the disease course and reduced mortality rates and the need for intubation. Published in the International Journal of Infectious Diseases, the results show Interleukin-6 inhibitors…
-
Noosa News24 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
Noosa News23 hours agoDefence investigation finds Taipan pilot’s actions possibly prevented further fatalities in crash
-
Noosa News22 hours agoNo matter what happens in his Origin debut, history beckons for rookie maroon Robert Toia
-
General20 hours agoDairy farmers devastated by floods across parts of New South Wales